The most common side effects of glp 1 ras are injection site reactions nausea and diarrhea because of the slowed gastric emptying.
Glp 1 ra side effects.
There is some dispute over the safety profile of these drugs due to proliferative effects in the pancreas.
Some side effects are warning signs of serious conditions.
Feelings of early fullness lower appetite nausea vomiting diarrhea.
Other common adverse effects include injection site reactions headache and nasopharyngitis but these effects do not usually result in discontinuation of the drug.
Diabetes is associated with both acute pancreatitis and pancreatic cancer.
The most common symptoms associated with the use of glp 1 receptor agonists are gastrointestinal symptoms mainly nausea.
Diarrhoea nausea vomiting headaches dizziness increased sweating indigestion constipation loss of appetite.
However it has been found to exert many other effects in glucose metabo lism.
For example nausea and vomiting with abdominal pain could be pancreatitis inflammation of the pancreas.
Glp 1 was initially thought to primarily affect insulin release.
Glp 1 receptor agonists can cause nausea vomiting diarrhea headache weakness or dizziness.
Ask your doctor which signs to watch for and what to do if those signs happen.
Glp 1 as has a short duration of action so to overcome this limitation several modifications either in the drug or the formulations are being developed.
But the risk of low blood sugar levels is usually only increased if you re taking another medication known to lower blood sugar at the same time such as sulfonylureas or insulin.
Glp 1 ras commonly cause digestive side effects such as.
This usually resolves after a few weeks and many clinicians start the drug at a low dose and titrate up to help decrease or prevent these side effects.
A recent study suggests glp 1 receptor agonists may be more likely to cause diabetes patients nausea diarrhea vomiting and other gastrointestinal adverse effects at certain doses and in certain combinations with other medications these findings show that the gastrointestinal adverse effects are according to the study abstract related to dose and background medications especially metformin and may vary in a compound specific manner.
Low blood sugar levels hypoglycemia are a more serious risk linked to the glp 1 class of medications.
